Skip to main content

Molecular iodine exerts antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts



The immune system is a crucial component in cancer progression or regression. Molecular iodine (I2) exerts significant antineoplastic effects, acting as a differentiation inductor and immune modulator, but its effects in antitumor immune response are not elucidated.


The present work analyzed the effect of I2 in human breast cancer cell lines with low (MCF-7) and high (MDA-MB231) metastatic potential under both in vitro (cell proliferation and invasion assay) and in vivo (xenografts of athymic nude mice) conditions.


In vitro analysis showed that the 200 μM I2 supplement decreases the proliferation rate in both cell lines and diminishes the epithelial-mesenchymal transition (EMT) profile and the invasive capacity in MDA-MB231. In immunosuppressed mice, the I2 supplement impairs implantation (incidence), tumoral growth, and proliferation of both types of cells. Xenografts of the animals treated with I2 decrease the expression of invasion markers like CD44, vimentin, urokinase plasminogen activator and its receptor, and vascular endothelial growth factor; and increase peroxisome proliferator-activated receptor gamma. Moreover, in mice with xenografts, the I2 supplement increases the circulating level of leukocytes and the number of intratumoral infiltrating lymphocytes, some of them activated as CD8+, suggesting the activation of antitumor immune responses.


I2 decreases the invasive potential of a triple negative basal cancer cell line, and under in vivo conditions the oral supplement of this halogen activates the antitumor immune response, preventing progression of xenografts from laminal and basal mammary cancer cells. These effects allow us to propose iodine supplementation as a possible adjuvant in breast cancer therapy.

Peer Review reports


Metastasis is a major cause of death in patients diagnosed with breast cancer [1]. Epithelial-mesenchymal transition (EMT) is a complex process that confers tumorous cells the ability to detach from the original tumor site. This process is accompanied by a reduced expression of proteins involved in cell-cell adhesion, including E-cadherin, and an increase in proteins associated with cell motility and invasion, such as vimentin and CD44 [2]. Invasiveness requires the activation of components like matrix metalloproteinases and mediators of angiogenesis and metastasis, including vascular endothelial growth factor (VEGF) and transforming growth factor β (TGF-β) [3,4,5]. Other signals recently recognized as essential for cancer promotion and metastasis are the pro-inflammatory factors present in the tumor microenvironment [6]. Several studies have shown that the immune system participates differentially in either elimination or progression of tumor cells, yet the equilibrium between these two effects has not been well established [7]. Some authors suggest that neoplastic cells and B cells suppress the immune system, promoting the proliferation and differentiation of lymphocytes to the regulatory T (Treg, FOXP3+) phenotype and the up-regulation of macrophage scavenger receptor 1 (MSR1) of dendritic cells, thus maintaining the inflammatory environment and promoting T cell exhaustion in T effector cells [8,9,10]. These conditions facilitate intravasation into the circulatory system and allow metastatic dissemination of the cancer cells [6, 10]. On the other hand, recent data have shown that restoring T cell function is possible with therapies that include radiation, vaccination (Her2 or immune reactive products), or metronomic chemotherapy [10,11,12,13]. The mechanisms by which these therapies enhance the proliferation, differentiation, and activity of the anti-tumor immune response could involve modifications in both tumoral and immune cells. For instance, there are reports on the induction of anti-angiogenic effects, re-differentiation or cellular death, and/or activation of cellular stress pathways that could reinitiate a targeted immune response at tumoral levels [12]. Studies concerning the immune system have demonstrated the direct reduction of Treg cells by inhibiting their suppressive function; as well as the induction of proliferation/differentiation/maturation of lymphocyte helper type 1 (Th1, CD4+), cytotoxic (CTL, CD8+), natural killer (NK, CD56+), and/or dendritic cells in antitumor immune re-activation [13].

Previous studies have shown that molecular iodine (I2) exerts an antineoplastic effect, triggering apoptotic and re-differentiation mechanisms in several cancer cells [14]. In addition, I2 has been proposed as an immune modulator. It is demonstrated that several immune cell types can internalize iodine, which could act as an antibacterial, anti-inflammatory, or as an inductor of immune response depending on the cellular context [15, 16]. However, specific effects of this element on tumor immune response have not been evaluated. The goal of this study was to analyze the role of I2 in the proliferation and invasive potential of human breast cancer cell lines with low (MCF-7) and high (MDA-MB231) metastatic potential under both in vitro (cell proliferation and invasion assay) and in vivo (xenografts) conditions. Athymic nude Foxn1 nu/nu mice were used as a model of reactivation of the immune response; despite the congenital absence of a thymus in these animals, the few T cells present in the spleen and lymph nodes are susceptible to stimulation and rouse an antitumor response [17, 18].



Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), penicillin, streptomycin, and trypsin-EDTA solutions were provided by GIBCO-BRL (Grand Island, NY, USA). Sublimed iodine was obtained from J.T. Baker (Estado de México, México). The concentration of iodine solutions was confirmed by titration with sodium thiosulfate [19].

Cell culture and I2 effect in vitro

Normal MCF-12F (CRL-10783), tumorous estrogen receptor-positive MCF-7 (HTB-22), and triple-negative MDA-MB-231 (HTB-26) human breast epithelial cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin (basal medium) at 5% CO2 and 37 °C for 24 h before treatments.

MTT viability assay

Cell viability was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded at 5 × 103 cells/well in DMEM basal medium and incubated at 37 °C in 96-well plates with 5% CO2. After incubation overnight, the basal medium in each well was replaced with media containing one of the several concentrations of I2 and incubated for 48 h; 20 μL of MTT (5 mg/mL in PBS) was added to each well, and cells were incubated for 4 h at 37 °C. The supernatants were removed, 200 μL of dimethyl sulfoxide (DMSO) was added, and the absorbance (570 nm) was determined by a microplate reader (Bio-Rad, Hercules, CA, USA). Cell viability was expressed as percent change over control and calculated using the formula: (mean OD of treated cells/mean OD of untreated control cells) × 100.

Invasive capacity

Invasive capacity was measured using a Transwell chamber coated with 30 μL Matrigel (reconstituted basement membrane; BD Biosciences, Mississauga, Canada). MDA-MB231 cells (2.5 × 104 per Transwell) were incubated in a basal medium made with 200 μM I2 or deionized water, in 5% CO2 and at 37 °C. Cells in the upper chamber were removed with a cotton swab after 24 h. The cells remaining in the membrane were fixed using methanol for 10 min, then stained with 1% crystal violet solution and washed with PBS. The number of invading cells per field of view was counted at 20X magnification.

Xenografts and I2 effect in vivo

Sixty-four female athymic hetero- and homozygous nude mice (Foxn1 nu/nu; Harlan Mexico, CDMX, Mexico) were kept in the specialized vivarium facility (semi-barrier) under controlled temperature conditions (22 ± 1 °C) on a 12-h:12-h light-dark cycle at 50% humidity. The home cage (Super Mouse AllerZone™, Micro-Isolator™ 1800™, LabProducts Inc. Houston, TX, USA) contained air filters, and mice were allowed ad libitum access to food (Purina certified rodent chow, Ralston Purina Co., St. Louis, MO, USA) and water. The procedures followed the Animal Care and Use Program of the National Institutes of Health (NIH, Bethesda, MD, USA) and were approved by the Research Ethics Committee of the Institute of Neurobiology (INB-UNAM) (Protocol #035).

All procedures were performed in the morning (8:00 am to 12:00 pm). Cells were implanted, and mice were sacrificed under anesthesia with a mixture of ketamine/xylazine (30 and 6 mg/kg body weight, respectively). When homozygous nude mice were six weeks old, they were injected subcutaneously with 5 × 106 cells of either the MCF-7 or the MDA-MB231 cell line in 50 μl PBS and 50 μl Matrigel. At 48 h post-inoculation, the mice were randomly divided into the control and iodine-treated groups (10–12 animals per group) (Additional file 1). Drinking water for the control group was deionized (6.76 ± 1.0 ml/animal/day) and supplemented with 0.025% I2 (6.4 ± 1.2 ml/animal/day) for each cage (3 animals per cage) of the iodine group (1.35–1.62 mg I2/animal/day). All animals were monitored every week for six weeks to identify body weight gain and tumoral growth. Tumor sizes were calculated by the ellipsoid formula [19]. In all animals, a necropsy was performed after sacrifice in open total body and in three tissues (e.g., lung, liver or skin around the tumors) to screen for possible metastases or alterations (e.g., ascites, inflammation, constipation).

To analyze the effect of iodine on the general immune response, hetero- and homozygous 6-week-old mice (10 animals per group) were supplemented with deionized water or 0.025% I2 for 6 weeks. Mice were sacrificed by decapitation, and blood was collected separately in sterile tubes with EDTA. White blood cells were counted using a hemocytometer. Ten microliters of blood were diluted 1:20 in Türk’s solution (Hycel Lab, Edo Mexico, Mexico) based on leukocyte staining with gentian violet.

Immunohistochemistry for proliferating cell nuclear antigen and immunofluorescence for CD8+

First, three-micron slices of xenografts were deparaffinized and treated with 10 mM sodium citrate for 20 min at 80 °C for antigen retrieval. After maintaining at 25 degrees for cooling, slices were incubated with 0.3% hydrogen peroxide for blocking the activity of endogenous peroxidase. Non-specific binding was prevented with 2% non-fat dried milk in PBS buffer with 20% fetal bovine serum (at 37 °C for 1 h). Slices were incubated with the anti-rat monoclonal antibody against proliferating cell nuclear antigen (PCNA) generated in mouse, clone PC10 (DakoCytomation, Carpinteria, CA, USA). Followed of an incubation in a humid chamber at room temperature for 30 min. Immunocomplexes were identified by using goat anti-mouse antibody, coupled to peroxidase (EnVision™ + System, peroxidase, DakoCytomation, Carpinteria, CA, USA). The complex of Diaminobenzidine (DAB)/peroxidase/hematoxylin was used as the chromogenic substrate and was mounted (Merk, Darmstadt, Germany). As isotype control antibodies, tumor slices were incubated without either the primary or secondary antibody. The percentage of PCNA-positive cells was quantified by counting the number of labeled cells in at least 500 cells per region, and three random regions were analyzed [19].

CD8+ lymphocytes were analyzed in MDA-MB231 xenografts, and a lymph node from heterozygotic mice was used as a positive control. Slide preparation was carried out for visualization by confocal microscopy (Zeiss LSM 780; Jena, Germany). After antigen retrieval, slides were incubated for 20 min in 70% ethanol with 0.1% Sudan Black B (Sigma-Aldrich, Estado de Mexico, Mexico) to reduce autofluorescence. Detection of CD8 protein was carried out by primary monoclonal antibody (monoclonal CD8-PE 55032, 1:50, BD Biosciences, USA), and nuclei were observed using DAPI (1:100, Life Technologies). Slides were mounted using 4% antifade reagent (4% n-propyl gallate, 1% DABCO) and observed at 63X magnifications. Samples were excited using 633 nm (1.0% laser) and 488 nm (1.0% laser) wavelengths. Quantification was done by counting the CD8+ lymphocytes per field (Z-stack projection) and reported as the mean of the three fields randomly taken for each tumor.

Histopathological analysis

Fixed xenografts were embedded in paraffin. From each block, sections of 3-μm width were cut and then placed on slides treated with 3-aminopropyltriethoxysilane. Hematoxylin and eosin (H&E) staining was used to observe histopathological change, especially lymphocytic infiltration and necrotic areas. The number of lymphocytes was evaluated by two independent observers (XZ and CA) in anonymized and blinded samples. The average of three random regions at 40X magnification was analyzed and the quantification was performed using ImageJ software (version 1.41, National Institutes of Health, Bethesda, MD, USA).

Quantitative real-time PCR (RT-qPCR)

Gene expression was quantified by the qPCR method previously described [19]. Total RNA was obtained according to protocol described by the manufacturer (TRIzol reagent, Life Technologies, Inc., Carlsbad, CA, USA). 2 μg total RNA were reverse transcribed (RT) using oligo-deoxythymidine primers. To eliminate the genomic DNA, the RT assay was carried out for each sample, as a control one tube with a pool of all samples without transcriptase enzyme (−RT) was used. Each PCR was made using a specific pair of oligos detailed in Table 1. The Rotor-Gene 3000 apparatus (Corbett Research, Mortlake, NSW, Australia) was employed to perform qPCR with a marker for DNA amplification (SYBR Green, Fermentas, Burlington, ON, Canada). Relative expression of genes was calculated by using a standard curve and normalized to β-actin expression, as a housekeeping gene. In all RT-qPCR assays, the coefficient of variation for each gene was less than 16%, demonstrating that changes observed in different experimental groups correspond to changes in the genes.

Table 1 Oligonucleotides

Protein quantification

CD24, CD44, peroxisome proliferator-activated receptors type gamma (PPARγ) and actin isoforms were analyzed by Western blot. Protein extracts were obtained from xenograft homogenates using RIPA buffer and mini-Complete EDTA protease inhibitor (Roche Diagnostics GmbH, Germany). Proteins were quantified by the Bradford method (Bio-Rad protein assay; Hercules, CA, USA). Samples containing 50 μg of protein were resolved through 15% SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad; Hercules, CA, USA) by electroblotting. Membranes were washed with TBS (Tris-buffered saline, pH 7.5) and blocked with 5% non-fat dry milk in TBST (TBS + 0.05% Tween 20) for 1 h at room temperature. Membranes were incubated overnight at 4 °C with anti-CD24, anti-CD44, anti-PPARγ and anti-Actin isoform antibodies (Santa Cruz, Santa Cruz, CA, USA). Antibody binding was detected using horseradish peroxidase secondary antibodies, and the detection was performed using an enhanced chemiluminescence (ECL) system (Bio-Rad; Hercules, CA, USA) according to the manufacturer’s instructions, followed by exposure to radiographic film (Dry Medical X-ray Film, FujiFilm, Edo Mexico, Mexico). Densitometry was performed using ImageJ software (version 1.41, National Institutes of Health, Bethesda, MD, USA).

Statistical analysis

Data in vitro are representative of three independent experiments by triplicate. The incidence of xenotransplanted mice treated with iodine was analyzed using 2 × 2 contingency tables and a Chi-square as post hoc test. The effects the other analysis were evaluated using Student’s t-test or one-way ANOVA followed by Tukey’s test. Values with P < 0.05 were considered statistically significant.


I2 supplementation disrupts cancer cell viability, decreasing epithelial-mesenchymal transition markers and the invasive potential

Fig. 1 summarizes the in vitro effects of the I2 supplement on cells from normal and cancerous mammary epithelia. Viability analyses (Fig. 1a) show that MCF-7 are the most sensitive cells, since their proliferation is significantly inhibited (30%) at 100 μM I2, reaching IC50 at a concentration of 204.7 μM. Tumor cells with a more aggressive phenotype (MDA-MB231) reached IC50 at a concentration of 409.5 μM I2. The viability of MCF-12F epithelial breast cells was affected by exposure to I2 from 400 μM (10%) and 600 μM (35%). Further analyses were carried out only in tumorous cells. Gene expression analysis were carried out after 48 h of 200 μM (MCF-7) and 400 μM (MDA-MB231) I2 treatment. I2 exerted significant changes only in MDA-MB231 cells, with decreases in the expression of CD44 (28%) and vimentin (22%). E-cadherin, which was undetectable in this cell type under control conditions, was significantly induced after 48 h of 400 μM I2 treatment (Fig. 1b). Invasive capacity analysis (Transwell assay) showed that 200 μM I2 is enough to compromise this capacity in MDA-MB231 cells, as 46% of invasive cells per area were diminished (Fig. 1c).

Fig. 1

Effect of molecular iodine (I2) on viability, epithelial-mesenchymal transition (EMT) and invasive potential in normal (MCF-12F) and cancerous (MCF-7 and MDA-MB231) mammary cells. a, Percentage of viable cells after incubation for 48 h in media containing iodine at the indicated concentrations, as determined by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Significant differences in * for mammary cancer MCF-7 cells, & for mammary cancer MDA-MB231 cells and in # for normal mammary epithelium MCF-12F cells (P < 0.05) between their respective control (one-way ANOVA and Tukey’s test). b, Cancerous cells incubated for 48 h in media containing 200 (MCF-7) and 400 (MDA-MB231) μM I2 were analyzed for mRNA expression for EMT markers CD24, CD44, E-cadherin (E-cad), and vimentin (Vim) by quantitative real-time PCR (RT-qPCR). Values were normalized to the amount of β-actin mRNA amplified. Ud, undetectable; *, significant differences vs. the control (Student’s t-test; P < 0.05). c, The invasiveness assay was performed to calculate the invasive capability of MDA-MB231 cells in presence of 200 μM I2. Images were taken at 20X magnification. Scale bar, 100 μm. Number of cells ± SD that penetrated the membrane. *Significant difference between treated and untreated MDA-MB231 cells (Student’s t-test, P < 0.05) (n = 3 individual samples)

Oral I2 supplementation impaired cancer implantation and tumor growth, thus preventing weight loss

For in vivo studies, all animals were manipulated daily for one week before starting the treatments (inoculated with the cell lines [xenografts] and at the beginning of 0.025% I2 supplementation in drinking water) to diminish the handing stress. As shown in Fig. 2a, both cell lines in control groups developed efficiently into tumors at an incidence of 91.6% (11 of 12 animals) in MCF-7 and 100% (12 of 12) in MDA-MB231. In I2-supplemented animals, the implantation and tumor growth were significantly impaired in both groups: 50% (6 to 12) in MCF-7 and 25% (3 to 12) in MDA-MB231. In fact, in MDA-MB231 + I2, a second group of 10 animals (2 to 10) had to be incorporated to obtain at least five samples of tumors from this group (Fig. 2a). Animals continuously supplemented (6 weeks) with 0.025% I2 solution developed significantly smaller tumors than those in their respective controls (0.4–0.5 vs. 1.4–2.4 cm3), indicating that the presence of I2 impaired the tumor growth (Fig. 2b). The animals implanted showed a significant decrease in their body weight gain (18–20%) in comparison with those implanted and supplemented with I2 or with the control groups not implanted (homo or heterozygous). The analysis between tumor size and weight loss showed that only the implanted MDA-MB231 group, which developed the largest tumors, exhibited a clear but non-significant inverse correlation (P = 0.0852) suggesting the possible establishment of cachexia, known for its association with cancer (Fig. 2d). The necropsy analysis showed that none of the animals exhibited metastasis, adverse conditions in general (ascites or constipation), or visible lesions or metastasis in lung, liver or side-skin of the tumorous region (data not shown).

Fig. 2

Effect of I2 supplement on tumoral incidence, tumoral volume and body weight gain in animals with xenografts of cancer cells. Female athymic homozygous (Foxn1 nu/nu) mice were inoculated with 5 × 106 cells of each cell line in 50 μl PBS and 50 μl Matrigel. The drinking water and the water used for 0.025% I2 solution were always deionized. The water supplement (alone or with I2) began 48 h after cell inoculation and was maintained throughout the study. Parameters were analyzed after 6 weeks of inoculations. a, Tumoral incidence. Number of animals that presented observable tumorous mass (0.2 cm3). A second group of animals with 10 animals was incorporated to obtain five samples of xenografts from the MDA-MB231+ I2 group. * Significant differences between I2-treated mice and control mice using Chi-square test. b, Final tumoral volume. Each dot represents an individual tumor by each group. Data are expressed ± SD. * Significant difference (Student’s t-test; P < 0.05) between their respective control. Photographs of representative tumor mass for each group. c, Body weight gain. Lines represent the body weight gain in animals implanted with xenografts and supplemented or not with 0.025% I2 for 6 weeks. The graph also shows the weight recorded for homo and heterozygous non-implanted animals (with and without I2 supplement) at 0, 3 and 6 weeks. Data are expressed ± SD. * Significant difference, one-way ANOVA and Tukey’s test. d, Correlation analysis. Linear regression between final tumor volume (cm3) and final body weight (6th week) in implanted homozygous mice with and without I2 supplement. P value for MCF-7, 0.6661; MCF-7 + I2, 0.9629; MDA-MB231, 0.0852; MDA-MB231 + I2, 0.2865. No significant differences were found

The declined expression of EMT, invasive and cachexia markers were related to PPARγ over-expression

Xenografts of 0.025% I2-supplemented mice showed significant decreases (25 to 30%) in cell proliferation as measured by positive cells to PCNA protein in both cell types (Fig. 3). Also, both I2-supplemented groups showed a clear decline in the expression of markers related to stem cell condition (CD24, CD44 protein), invasion (VEGF, urokinase plasminogen activator [uPA], and uPA receptor [uPAR]), immunomodulation (TGF-β), or inflammation/cachexia inductor (tumor necrosis factor alpha; TNF-α), which was more evident in MDA-MB231 + I2 (Fig. 4a-c), suggesting that I2 actions are related with diminishing the stem condition and invasive potential of these cells. In contrast, PPARγ expression (mRNA and protein) exhibited a significant increase in I2-supplemented groups in comparison with control groups, suggesting the participation of these receptors in I2 actions (Fig. 4a and b).

Fig. 3

Proliferation rate. Immunohistochemistry showing the presence of PCNA-positive cells in xenografts from animals supplemented with or without 0.025% I2 in drinking water for six weeks. Percentage of PCNA-positive cells was quantified by counting the number of labeled cells in at least 500 cells per region, and three random regions were analyzed. Images were taken at 20X magnification. Data are expressed as the mean ± SD (n = 6). *Significantly different from its control (Student’s t-test; P < 0.05)

Fig. 4

Effect of I2 supplement on expression of invasive and inflammatory markers in xenografts. Nude mice were supplemented with or without 0.025%I2 in drinking water for six weeks. a, Representative Western blot of CD24, CD44 and PPARγ proteins from MCF-7 and MDA-MB231 samples. Equal amounts of protein were loaded on each lane (50 μg), and Actin was run as a control for loading and exposure time (two independent experiments were performed). b and c, mRNA expression for vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), uPA receptor (uPAR), tumor necrosis factor alpha (TNFα), transforming growth factor beta (TGF-β), and peroxisome proliferator-activated receptor gamma (PPARγ) were analyzed by RT-qPCR. Values were normalized to the amount of β-actin mRNA amplified (n = 5–6 individual samples). Ud, undetectable. * Significant differences vs. the control (Student’s t-test; P < 0.05)

I2 supplementation increased the immune antitumor response in homozygous implanted animals

To analyze the immune response associated with I2 supplementation, we compared the circulating and tumor immune cells in control and I2-supplemented hetero- and homozygous nude mice. The homozygous animals include groups with and without MDA-MB231 xenografts. As shown in Fig. 5a, homozygous animals exhibited significantly low circulating levels of leukocytes in comparison to heterozygous mice. I2 supplementation did not exert any change in heterozygous animals. In homozygous animals, the total leukocyte count had a tendency (not statistically significant) to decrease in non-implanted mice, whereas in implanted ones this concentration tended to increase (Fig. 5a). This last response seems to be related to a rise in the percentage of circulating lymphocytes (12%) and granulocytes (27%) in these groups. Monocytes showed no changes (Fig. 5b). These results agree with the significant amount (three-fold more than control) of lymphocytic infiltration (H&E) observed in tumor samples from I2-supplemented animals (Fig. 6a), some of which were positive to the CD8 marker (Fig. 6b). Moreover, the xenografts from I2-treated animals showed evident necrotic areas (Fig. 6c). These results suggest the activation of an antitumor immune response secondary to I2 supplementation.

Fig. 5

Effect of I2 supplement on circulating immune leucocytes. Six-week-old hetero- and homozygous nude mice (with and without MDA-MB231 xenografts) were supplemented with or without 0.025% I2 (in drinking water for 6 weeks. a, The number of leukocytes in peripheral blood was determined by direct counting after dilution with Turk’s solution. b, Peripheral blood populations of leukocytes were separated and quantified by FACS (cytometric images). Differential quantification (lower panel). Data are expressed as the mean ± SD (n = 8–10 animals per group). Different letters denote statistical differences (one-way ANOVA, Tukey’s test; P < 0.05)

Fig. 6

Effect of I2 supplement on tumoral immune response. a, Micrographs stained with H&E (20X), insert 2X+ zoom of photograph shown lymphocytes (hyperpigmented cells). b, Confocal immunofluorescence (63X) of lymph node (positive control) and MDA-MB231 xenografts (Control and I2) with antibody against CD8 protein (red). Insert: zoom 2X+ to visualize CD8+ lymphocytes (red stain in cytoplasm). Nuclei were stained with DAPI (blue). The analysis was performed as the average of three random fields and the quantification was performed using the ImageJ 1.47 software. Data are expressed as the mean ± SD (n = 6). *Significantly different from control (Student’s t-test; P < 0.05). c, Representative micrographs from necrotic areas (red arrows) from MDA-MD231 + I2 xenografts (H&E, 20X)


In the present report, we analyze the effect of iodine on two types of mammary tumor cell lines that represent epithelial breast cancers. The first is laminal estrogen responsive, which exhibits low invasive potential (MCF-7), and the second is a basal triple negative with elevated invasive potentiality (MDA-MB231). In the in vitro studies, we corroborated previous reports that described that several types of cells exhibited different susceptibility to I2, and that the normal types (like MCF-12F) are less sensitive to this halogen [20,21,22]. This finding has been explained in part by the presence of high concentrations of arachidonic acid in tumorous cells, where I2 binds to generate the active iodolipid known as 6-iodolactone, a specific ligand of PPARγ [23]. PPARs are ligand-activated transcription factors initially described as molecular regulators of lipid metabolism. However, PPARγ was recently shown to play a significant role in decreasing cell proliferation and inducing differentiation and apoptosis in many types of cancer [24]. The present results are consistent with previous studies from our laboratory showing that I2 supplementation increases PPARγ expression under in vivo and in vitro conditions [19, 25]. The in vitro data showed a marked effect of I2 inhibiting the proliferation of MCF-7; however, the anti-invasive gene response (stem and EMT markers) was evidenced primarily in the MDA-MB231 cells, suggesting an important effect of this halogen on the tumorigenic potential. Previous reports have shown that CD44 knockdown in MDA-MB231 cells decreases their metastatic capacity in invasive in vitro assay [26] and that the activation of CD44 results in increased transcription and synthesis of several matrix metalloproteinases, including those in the uPA and uPAR families [27]. The significant decrease in CD44, VEGF, uPA and uPAR expression shown here in tumors from I2-treated mice could be additional evidence that PPARγ receptors participate in the antineoplastic effect of I2. It has been reported that VEGF and uPA or CD133 and CD44 expressions are inhibited when PPARγ is activated by agonists like rosiglitazone [28] or celecoxib [29], respectively.

The results obtained in vivo show that the significant antineoplastic effect of I2 on tumoral growth was accompanied by similar changes in invasive markers observed in vitro, suggesting that tumoral cells maintain their sensitivity to iodine. Interestingly, I2 supplementation prevented an 18–20% body weight loss observed in control implanted mice. This weight loss has been described as part of cachexia installation, which is associated with cancer progression, in preclinical [30] and clinical studies [31]. Cachexia is defined as a multifactorial syndrome with alterations in skeletal muscle mass and/or metabolic equilibrium related to an increase in pro-inflammatory cytokines such as TNF-α, interleukin 6 (IL-6), IL-8, and interferon gamma (IFN-γ) [31]. In implanted I2-treated animals, the body weight gain was similar to that of heterozygous and non-implanted homozygous nude mice (exposed or not to I2 supplement). All these changes in weight were not related to the tumor size or to deleterious conditions (ascites, constipation or metastasis), suggesting that iodine supplementation prevents cachexia to hinder cancer progression by maintaining a small tumor size and decreases markers like TNF-α in tumorous cells.

The present work also analyzes the effect of I2 supplementation on the interaction tumor/T cell immune response. The capacity of athymic mice to develop xenografts has been attributed to multiple immunological defects, including reduced interferon-γ production by dendritic cells and functional incompetence of T cells. However, a small proportion of T lymphocyte cells has been detected in these animals, and stimulation with several agents like IL-2 or TNF-α induces the regression of xenografts, indicating the potential reactivation of these cells [32, 33]. Similarly, data in the present work show significantly low circulating leukocytes in homozygous animals, thus corroborating their immunosuppressed condition as well as a clear modulation of the immune system when they were supplemented with iodine. We found that the I2 supplement benefits homozygous animals in control conditions (tendency to decrease circulating leukocytes) and in the presence of xenografts to induce activation of the immune system with general (circulating levels) and local anti-tumoral responses (increased CD8+ lymphocytic infiltration and several necrotic areas in their reduced xenografts). The mechanisms involved in I2 effects could be explained by the actions of this element. In control conditions is secondary to the rapid and efficient antibacterial effect of I2. I2 and HIO species are characterized by their high capacity to oxidize biological components like lipids and account for the biocide action of I2 solutions [34,35,36]. In this scenario, circulating I2 prevents microorganism proliferation, making an immune response unnecessary or attenuated. In implanted mice, I2 could act on tumoral cells through PPARγ activation, forcing re-differentiation or death to reinitiate the targeted immune response [29], or acting directly on immune cells by inducing the reactivation of T cells. In this regard, several reports suggest that the well-known beneficial effect of I2 on chronic lesions involves immune responses as well as antibacterial effects [15]. In chronic wounds, its presence activates the influx of macrophages and T cells [37], and under in vitro conditions, I2 enhances leukocyte Th1 responses like IL-10, IL8-CXCL8 and IL6 [16]. Moreover, in a recent report from our laboratory we describe that the successful doxorubicin/I2 treatment against canine mammary cancer includes the activation of antitumor immune response [38]. The mechanisms by which I2 exerts these activations have not been analyzed but could involve the direct antioxidant/oxidant effects or indirect action by PPARγ activation. In the study using metronomic therapy with cyclophosphamide, the antitumor immune response was associated with a consistent activation of the immune cascade (STAT1, interferon and stimulation of cell death), suggesting PPARγ as the main inducer [39].


I2 supplementation decreases the invasive potential of triple negative basal cancer cells MDA-MB231 under in vivo and in vitro conditions. Moreover, oral I2 supplementation activates the antitumor immune response in two types of breast cancer cell xenografts (laminal or basal), preventing their tumorigenic progression. Although additional studies with several breast cancer cells type are necessary, the present results allow us to propose I2 as a possible adjuvant in breast cancer therapy.


  1. 1.

    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86.

    CAS  Article  Google Scholar 

  2. 2.

    Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006;25(15):2273–84.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 2014;16(4):428.

    PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside. Crit Rev Oncol Hematol. 2015;94(1):45–54.

    PubMed  Article  Google Scholar 

  5. 5.

    Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Schwartz M, Zhang Y, Rosenblatt JD. B cell regulation of the anti-tumor response and role in carcinogenesis. J Immunother Cancer. 2016;4(1):40.

    PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Gocheva V, Wang H-W, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010;24(3):241–55.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Mendes F, Domingues C, Rodrigues-Santos P, Abrantes AM, Gonçalves AC, Estrela J, et al. The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation. Biochim Biophys Acta. 2016;1865(2):168–75.

    CAS  PubMed  Google Scholar 

  11. 11.

    Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, et al. Dendritic cell vaccination enhances immune responses and induces regression of HER2pos DCIS independent of route: results of randomized selection design trial. Clin Cancer Res. 2016;23(12):2961–71.

    PubMed  Article  Google Scholar 

  12. 12.

    Mross K, Steinbild S. Metronomic anti-cancer therapy–an ongoing treatment option for advanced cancer patients. J Can Res Ther. 2012;1(1):32.

    Article  Google Scholar 

  13. 13.

    Datta J, Berk E, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Rationale for a multimodality strategy to enhance the efficacy of dendritic cell-based cancer immunotherapy. Front Immunol. 2015;6:271.

    PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Aceves C, Anguiano B, Delgado G. The extrathyronine actions of iodine as antioxidant, apoptotic, and differentiation factor in various tissues. Thyroid. 2013;23(8):938–46.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Hoekstra MJ, Westgate SJ, Mueller S. Povidone-iodine ointment demonstrates in vitro efficacy against biofilm formation. Int Wound J. 2017;14(1):172–9.

    PubMed  Article  Google Scholar 

  16. 16.

    Bilal MY, Dambaeva S, Kwak-Kim J, Gilman-Sachs A, Beaman KD. A role for iodide and thyroglobulin in modulating the function of human immune cells. Front Immunol. 2017;8:1573.

    PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Ritsma L, Dey-Guha I, Talele N, Sole X, Salony CJ, et al. Integrin beta1 activation induces an anti-melanoma host response. PLoS One. 2017;12(4):e0175300.

    PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Ikehara S, Pahwa RN, Fernandes G, Hansen CT, Good RA. Functional T cells in athymic nude mice. PNAS. 1984;81:886–8.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    García-Solís P, Alfaro Y, Anguiano B, Delgado G, Guzman RC, Nandi S, et al. Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I 2) but not by iodide (I−) treatment: evidence that I2 prevents cancer promotion. Mol Cell Endocrinol. 2005;236(1):49–57.

    PubMed  Article  Google Scholar 

  20. 20.

    Arroyo-Helguera O, Rojas E, Delgado G, Aceves C. Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects. Endocr Relat Cancer. 2008;15(4):1003–11.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Rosner H, Torremante P, Moller W, Gartner R. Antiproliferative/cytotoxic activity of molecular iodine and iodolactones in various human carcinoma cell lines. No interfering with EGF-signaling, but evidence for apoptosis. Exp Clin Endocrinol Diabetes. 2010;118(7):410–9.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Aranda N, Sosa S, Delgado G, Aceves C, Anguiano B. Uptake and antitumoral effects of iodine and 6-iodolactone in differentiated and undifferentiated human prostate cancer cell lines. Prostate. 2013;73(1):31–41.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Nuñez-Anita R, Arroyo-Helguera O, Cajero-Juárez M, López-Bojorquez L, Aceves C. A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplasic effect of iodine in mammary cancer. Prostaglandins Other Lipid Mediat. 2009;89(1):34–42.

    PubMed  Article  Google Scholar 

  24. 24.

    Woo CC, Loo SY, Gee V, Yap CW, Sethi G, Kumar AP, et al. Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-γ pathway. Biochem Pharmacol. 2011;82(5):464–75.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Nava-Villalba M, Nuñez-Anita RE, Bontempo A, Aceves C. Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone. Mol Cancer. 2015;14(1):168.

    PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    McFarlane S, Coulter JA, Tibbits P, O'Grady A, McFarlane C, Montgomery N, et al. CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget. 2015;6(13):11465–76.

    PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Montgomery N, Hill A, McFarlane S, Neisen J, O'Grady A, Conlon S, et al. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res. 2012;14(3):R84.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Sawai H, Liu J, Reber HA, Hines OJ, Eibl G. Activation of peroxisome proliferator-activated receptor-γ decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res. 2006;4(3):159–67.

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Moon CM, Kwon J-H, Kim JS, Oh S-H, Jin Lee K, Park JJ, et al. Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. Int J Cancer. 2014;134(3):519–29.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Winje IM, Sheng X, Hansson KA, Solbra A, Tennoe S, Saatcioglu F, et al. Cachexia does not induce loss of myonuclei or muscle fibers during xenografted prostate cancer in mice. Acta Physiol (Oxf). 2018:e13204.

  31. 31.

    Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.

    PubMed  Article  Google Scholar 

  32. 32.

    Liebman MA, Roche MI, Williams BR, Kim J, Pageau SC, Sharon J. Antibody treatment of human tumor xenografts elicits active anti-tumor immunity in nude mice. Immunol Lett. 2007;114(1):16–22.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Kim DW, Andres ML, Li J, Kajioka EH, Miller GM, Seynhaeve AL, et al. Liposome-encapsulated tumor necrosis factor-α enhances the effects of radiation against human colon tumor xenografts. J Interf Cytokine Res. 2001;21(11):885–97.

    CAS  Article  Google Scholar 

  34. 34.

    Venturi S. Evolutionary significance of iodine. Current Chem Biol. 2011;5(3):155–62.

    CAS  Google Scholar 

  35. 35.

    Zhao D, Lim C-P, Miyanaga K, Tanji Y. Iodine from bacterial iodide oxidization by Roseovarius spp. Appl Microbiol Biotechnol. 2013;97(5):2173–82.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Chen X, Liu L, Yao P, Yu D, Hao L, Sun X. Effect of excessive iodine on immune function of lymphocytes and intervention with selenium. J Huazhong Univ Sci Technolog Med Sci. 2007;27(4):422–5.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Moore K, Thomas A, Harding K. Iodine released from the wound dressing Iodosorb modulates the secretion of cytokines by human macrophages responding to bacterial lipopolysaccharide. Int J Biochem Cell Biol. 1997;29(1):163–71.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Zambrano-Estrada X, Landaverde-Quiroz B, Duenas-Bocanegra AA, De Paz-Campos MA, Hernandez-Alberto G, Solorio-Perusquia B, et al. Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer. BMC Vet Res. 2018;14(1):87.

    PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Doloff JC, Waxman DJ. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts. BMC Cancer. 2015;15(1):375.

    PubMed  PubMed Central  Article  Google Scholar 

Download references


The authors are grateful to Brenda Ugalde Villanueva, Elsa Nydia Hernández Ríos, Maarten C Werdler, Martín García Servín, Alejandra Castilla and Laura Ines García for technical assistance; to Francisco Javier Valles and Rafael Silva for bibliographic assistance; to Leonor Casanova and Lourdes Lara for academic support; to Alberto Lara, Omar Gonzalez, Ramon Martinez, and Sandra Hernandez for computer assistance; and to Jessica Gonzalez Norris for proofreading.


This work was partially supported by grants PAPIIT-UNAM (201516, 209717) and CONACYT (176911, 235961). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author information




IM carried out tumorigenesis induction, animal experiments, and she prepared the manuscript. RENA analyzed the immune response and prepared the manuscript. EDG performed and analyzed the real-time polymerase chain reactions and Western blot. The analysis of the immune response was made by CA and XZE (lymphocytic infiltration, CD8 immunohistochemistry and necrotic areas), and MNV contributed to the in vivo experimental design and necropsy analysis. BA participated in designing the study and performed the statistical analysis. CA provided coordination and helped to design the study. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Carmen Aceves.

Ethics declarations

Ethics approval

All procedures followed the Animal Care and Use program (NIH, USA) and were approved by the Research Ethics Committee at INB (Protocol #035).

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1:

Description of animal’s conditions and procedures for iodine supplementation. Detailed description of the conditions of the animals used in this study, design of the randomized sample size, protocol for the supplementation of the drinking water with molecular iodine, in addition to detailed description of the quantification of the water consumption. (DOCX 15 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mendieta, I., Nuñez-Anita, R.E., Nava-Villalba, M. et al. Molecular iodine exerts antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts. BMC Cancer 19, 261 (2019).

Download citation


  • Molecular iodine
  • Mammary cancer
  • MCF-7
  • MDA-MB231
  • MCF-12F
  • Immune response
  • PPARγ
  • Iodine
  • Xenografts